Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans. Part A: Use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities
Carling J. Ursem, Naomi L. Kruhlak, Joseph F. Contrera, Philip M. MacLaughlin, R. Daniel Benz, Edwin J. MatthewsVolume:
54
Year:
2009
Language:
english
Pages:
22
DOI:
10.1016/j.yrtph.2008.12.009
File:
PDF, 315 KB
english, 2009